The company has received clinical approval for children's tetravalent influenza virus subunit vaccine, adult tetravalent influenza virus subunit vaccine, and 23-valent pneumococcal polysaccharide vaccine.

Using proprietary technology, the company has completed IND registration and obtained clinical approvals for both adult and pediatric formulations of its tetravalent influenza subunit vaccine. The Phase III clinical trial has been successfully concluded, and the vaccine is now awaiting NDA production approval.

This innovative product covers all four WHO-recommended influenza strains and offers superior purity and safety, making it particularly suitable for vulnerable populations including children and elderly patients. Its approval represents a significant milestone, positioning China's subunit influenza vaccine technology among the world's most advanced.

Additionally, the company's 23-valent pneumococcal polysaccharide vaccine is currently in Phase I clinical trials. Our robust pipeline includes simultaneous development of viral vaccine, bacterial vaccine, conjugate vaccine, viral recombinant subunit vaccine, and mRNA vaccine.